» Authors » Jean-Pierre Devogelaer

Jean-Pierre Devogelaer

Explore the profile of Jean-Pierre Devogelaer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 75
Citations 2245
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Phillips J, Subedi D, Lewis S, Keerie C, Cronin O, Porteous M, et al.
Ann Rheum Dis . 2023 Dec; 83(4):529-536. PMID: 38123339
Introduction: Paget's disease of bone (PDB) frequently presents at an advanced stage with irreversible skeletal damage. Clinical outcomes might be improved by earlier diagnosis and prophylactic treatment. Methods: We randomised...
2.
Huybrechts Y, De Ridder R, Steenackers E, Devogelaer J, Mortier G, Hendrickx G, et al.
Calcif Tissue Int . 2023 Sep; 113(5):552-557. PMID: 37728743
Paget's disease of bone (PDB) is a common, late-onset bone disorder, characterized by focal increases of bone turnover that can result in bone lesions. Heterozygous pathogenic variants in the Sequestosome...
3.
Cardinal M, Chretien A, Roels T, Lafont S, Ominsky M, Devogelaer J, et al.
Front Genet . 2021 Aug; 12:705505. PMID: 34447412
Osteogenesis imperfecta (OI), which is most often due to a collagen type 1 gene mutation, is characterized by low bone density and bone fragility. In OI patients, gender-related differences were...
4.
De Ridder R, Vandeweyer G, Boudin E, Hendrickx G, Huybrechts Y, Cremers T, et al.
Calcif Tissue Int . 2021 Jun; 109(6):656-665. PMID: 34173013
Paget's disease of bone (PDB) is a common bone disorder characterized by focal lesions caused by increased bone turnover. Monogenic forms of PDB and PDB-related phenotypes as well as genome-wide...
5.
Cronin O, Subedi D, Forsyth L, Goodman K, Lewis S, Keerie C, et al.
J Bone Miner Res . 2020 Mar; 35(7):1246-1252. PMID: 32176830
Mutations in SQSTM1 are strongly associated with Paget's disease of bone (PDB), but little is known about the clinical characteristics of those with early disease. Radionuclide bone scans, biochemical markers...
6.
Cardinal M, Dessain A, Roels T, Lafont S, Ominsky M, Devogelaer J, et al.
Calcif Tissue Int . 2020 Feb; 106(5):494-508. PMID: 32025752
In osteogenesis imperfecta (OI), vertebrae brittleness causes thorax deformations and leads to cardiopulmonary failure. As sclerostin-neutralizing antibodies increase bone mass and strength in animal models of osteoporosis, their administration in...
7.
Cronin O, Forsyth L, Goodman K, Lewis S, Keerie C, Walker A, et al.
BMJ Open . 2019 Sep; 9(9):e030689. PMID: 31488492
Introduction: Paget's disease of bone (PDB) is characterised by increased and disorganised bone remodelling affecting one or more skeletal sites. Complications include bone pain, deformity, deafness and pathological fractures. Mutations...
8.
Cardinal M, Tys J, Roels T, Lafont S, Ominsky M, Devogelaer J, et al.
Bone . 2019 May; 124:137-147. PMID: 31051315
Osteogenesis imperfecta type III (OI) is a serious genetic condition with poor bone quality and a high fracture rate in children. In a previous study, it was shown that a...
9.
De Ridder R, Boudin E, Vandeweyer G, Devogelaer J, Fransen E, Mortier G, et al.
Calcif Tissue Int . 2019 Feb; 104(6):613-621. PMID: 30726512
Paget's disease of bone (PDB) is a common, late-onset bone disorder characterized by focal increase of bone turnover. Mutations in the SQSTM1 gene are found in up to 40% of...
10.
Glorieux F, Devogelaer J, Durigova M, Goemaere S, Hemsley S, Jakob F, et al.
J Bone Miner Res . 2017 Apr; 32(7):1496-1504. PMID: 28370407
This 21-week, open-label, phase 2a trial aimed to evaluate the pharmacodynamics and safety of multiple, escalating infusions of BPS804, a neutralizing, anti-sclerostin antibody, in adults with moderate osteogenesis imperfecta (OI)....